Avantogen says RP101 extends survival in chemotherapy patients

By Elaine Rigoli

Tampa, Fla., Aug. 18 - Avantogen Oncology, Inc., a U.S. subsidiary of Avantogen Ltd., said preliminary results from a phase 1 dose-ranging study evaluating different doses of RP101 in combination with gemcitabine chemotherapy in patients with advanced pancreatic cancer produced a longer median survival when compared to patients treated with chemotherapy alone.

A preliminary analysis of the survival data from all 22 subjects followed for a median 12 months indicated a six-month survival rate of 68% and a 12-month survival rate of 39%.

An estimated median survival of 9.3 months was observed, which compares favorably to a median survival of about six months seen in several recent large randomized studies evaluating gemcitabine monotherapy and gemcitabine in combination with erlotinib or oxaliplatin, the company said in a news release.

There was no apparent difference in survival between the various dose groups of RP101, the release said.

Los Angeles-based Avantogen is an international biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.